Paik James M, Golabi Pegah, Younossi Youssef, Srishord Manirath, Mishra Alita, Younossi Zobair M
Betty and Guy Beatty Center for Integrated Research Inova Fairfax Medical Campus Falls Church VA.
Center for Outcomes Research in Liver Diseases Washington DC.
Hepatol Commun. 2020 Sep 14;4(12):1769-1780. doi: 10.1002/hep4.1599. eCollection 2020 Dec.
Chronic liver disease (CLD) is a growing cause of morbidity and mortality worldwide. The burden of CLD varies according to etiology and geographic location. We assessed the global burden of disability from the most important complications of CLD (cirrhosis and liver cancer [LC]) according to the most common etiologies between 2007 and 2017. We obtained years living with disability (YLD), years of life lost (YLL), and disability-adjusted life-years (DALYs) data from the Global Burden of Disease 2017 study. Between 2007 and 2017, LC DALYs decreased by 4.52% and cirrhosis DALYs decreased by 10.58%. Nevertheless, in 2017, CLD caused 62.16 million DALYs (33.4% LC and 66.5% cirrhosis), of which 96.8% came from YLL (34.1% LC and 65.9% cirrhosis) and 3.2% from YLD (11.6% LC and 88.4% cirrhosis). In 2017, Asia accounted for 66% of all DALYs globally. Central Asia, Africa regions, Southeast Asia, and Eastern Europe had the highest liver-related DALYs (≥1,000 per 100,000), whereas the lowest rates (≤500 per 100,000) were seen in high-income regions, such as Asia Pacific, North America, Western Europe, and Australasia. In 2007, hepatitis B virus caused the majority (47.5%) of liver-related DALYs, followed by hepatitis C virus (23.7%), alcoholic liver disease (14.2%), and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) (6.4%). In 2017, these rates shifted to 45.7%, 24.1%, 4.8%, and 7.1%, respectively. Between 2007 and 2017, cirrhosis-related DALYs due to NAFLD/NASH increased by 23.4%, whereas the increment was 37.5% for LC-related DALYs due to NAFLD/NASH. DALYs due to viral hepatitis still account for the largest proportion of CLD-related DALYs. Although DALYs from all other liver diseases have remained stable in the last decade, DALYs related to NAFLD/NASH are growing. National, regional, and global policies are needed to address the disability burden of NAFLD across the world.
慢性肝病(CLD)在全球范围内正成为发病率和死亡率上升的一个原因。CLD的负担因病因和地理位置而异。我们根据2007年至2017年间最常见的病因,评估了CLD最重要并发症(肝硬化和肝癌[LC])导致的全球残疾负担。我们从《2017年全球疾病负担》研究中获取了残疾生存年数(YLD)、寿命损失年数(YLL)和残疾调整生命年数(DALY)数据。2007年至2017年间,肝癌的DALY下降了4.52%,肝硬化的DALY下降了10.58%。然而,2017年,CLD导致了6216万DALY(肝癌占33.4%,肝硬化占66.5%),其中96.8%来自YLL(肝癌占34.1%,肝硬化占65.9%),3.2%来自YLD(肝癌占11.6%,肝硬化占88.4%)。2017年,亚洲占全球所有DALY的66%。中亚、非洲地区、东南亚和东欧的肝脏相关DALY最高(每10万人中≥1000),而在高收入地区,如亚太地区、北美、西欧和澳大拉西亚,这一比例最低(每10万人中≤500)。2007年,乙型肝炎病毒导致的肝脏相关DALY占多数(47.5%),其次是丙型肝炎病毒(23.7%)、酒精性肝病(14.2%)和非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NAFLD/NASH)(6.4%)。2017年,这些比例分别变为45.7%、24.1%、4.8%和7.1%。2007年至2017年间,NAFLD/NASH导致的肝硬化相关DALY增加了23.4%,而NAFLD/NASH导致的肝癌相关DALY增幅为37.5%。病毒性肝炎导致的DALY仍占CLD相关DALY的最大比例。尽管在过去十年中,所有其他肝病导致的DALY保持稳定,但与NAFLD/NASH相关的DALY正在增加。需要制定国家、区域和全球政策来应对全球范围内NAFLD的残疾负担。